Solid Biosciences (SLDB) Accumulated Expenses (2017 - 2026)

Solid Biosciences has disclosed Accumulated Expenses across 10 years of filings, most recently posting $19.2 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $19.2 million, up 31.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.2 million (up 31.6% YoY), and the FY2025 annual result was $18.9 million, down 4.57% from the prior year.
• Accumulated Expenses came in at $19.2 million for Q1 2026 at Solid Biosciences, up from $18.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.9 million in Q4 2024 to a low of $9.4 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $13.2 million (2024), against an average of $14.0 million.
• Across the five-year window, Accumulated Expenses surged 109.24% in 2022 and sank 39.12% in 2023, its largest moves.
• Solid Biosciences' Accumulated Expenses stood at $16.7 million in 2022, then tumbled by 39.12% to $10.2 million in 2023, then jumped by 95.37% to $19.9 million in 2024, then slipped by 4.57% to $18.9 million in 2025, then gained by 1.25% to $19.2 million in 2026.
• The last three Accumulated Expenses figures came in at $19.2 million (Q1 2026), $18.9 million (Q4 2025), and $19.0 million (Q3 2025), per Business Quant data.